Browse CELSR1

Summary
SymbolCELSR1
Namecadherin, EGF LAG seven-pass G-type receptor 1
Aliases HFMI2; FMI2; CDHF9; ADGRC1; flamingo homolog 2 (Drosophila); adhesion G protein-coupled receptor C1; cadheri ......
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00002 7 transmembrane receptor (Secretin family)
PF00028 Cadherin domain
PF00008 EGF-like domain
PF16489 GPCR-Autoproteolysis INducing (GAIN) domain
PF01825 GPCR proteolysis site
PF02793 Hormone receptor domain
PF00053 Laminin EGF domain
PF02210 Laminin G domain
Function

Receptor that may have an important role in cell/cell signaling during nervous system formation.

> Gene Ontology
 
Biological Process GO:0001736 establishment of planar polarity
GO:0001738 morphogenesis of a polarized epithelium
GO:0001763 morphogenesis of a branching structure
GO:0001764 neuron migration
GO:0001838 embryonic epithelial tube formation
GO:0001841 neural tube formation
GO:0001843 neural tube closure
GO:0001942 hair follicle development
GO:0003002 regionalization
GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules
GO:0007164 establishment of tissue polarity
GO:0007265 Ras protein signal transduction
GO:0007266 Rho protein signal transduction
GO:0007389 pattern specification process
GO:0007423 sensory organ development
GO:0007626 locomotory behavior
GO:0008105 asymmetric protein localization
GO:0008544 epidermis development
GO:0009952 anterior/posterior pattern specification
GO:0014020 primary neural tube formation
GO:0016055 Wnt signaling pathway
GO:0016331 morphogenesis of embryonic epithelium
GO:0021915 neural tube development
GO:0022404 molting cycle process
GO:0022405 hair cycle process
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0035148 tube formation
GO:0035239 tube morphogenesis
GO:0035567 non-canonical Wnt signaling pathway
GO:0042249 establishment of planar polarity of embryonic epithelium
GO:0042303 molting cycle
GO:0042471 ear morphogenesis
GO:0042472 inner ear morphogenesis
GO:0042633 hair cycle
GO:0043583 ear development
GO:0043588 skin development
GO:0045176 apical protein localization
GO:0045995 regulation of embryonic development
GO:0048104 establishment of body hair or bristle planar orientation
GO:0048105 establishment of body hair planar orientation
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048839 inner ear development
GO:0051493 regulation of cytoskeleton organization
GO:0060071 Wnt signaling pathway, planar cell polarity pathway
GO:0060425 lung morphogenesis
GO:0060441 epithelial tube branching involved in lung morphogenesis
GO:0060448 dichotomous subdivision of terminal units involved in lung branching
GO:0060488 orthogonal dichotomous subdivision of terminal units involved in lung branching morphogenesis
GO:0060489 planar dichotomous subdivision of terminal units involved in lung branching morphogenesis
GO:0060490 lateral sprouting involved in lung morphogenesis
GO:0060541 respiratory system development
GO:0060562 epithelial tube morphogenesis
GO:0060600 dichotomous subdivision of an epithelial terminal unit
GO:0060601 lateral sprouting from an epithelium
GO:0060606 tube closure
GO:0061138 morphogenesis of a branching epithelium
GO:0072175 epithelial tube formation
GO:0090175 regulation of establishment of planar polarity
GO:0090177 establishment of planar polarity involved in neural tube closure
GO:0090178 regulation of establishment of planar polarity involved in neural tube closure
GO:0090179 planar cell polarity pathway involved in neural tube closure
GO:0090251 protein localization involved in establishment of planar polarity
GO:0090596 sensory organ morphogenesis
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:0098773 skin epidermis development
GO:0198738 cell-cell signaling by wnt
GO:1905276 regulation of epithelial tube formation
GO:1905330 regulation of morphogenesis of an epithelium
GO:2000027 regulation of organ morphogenesis
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolCELSR1
Namecadherin, EGF LAG seven-pass G-type receptor 1
Aliases HFMI2; FMI2; CDHF9; ADGRC1; flamingo homolog 2 (Drosophila); adhesion G protein-coupled receptor C1; cadheri ......
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CELSR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCELSR1
Namecadherin, EGF LAG seven-pass G-type receptor 1
Aliases HFMI2; FMI2; CDHF9; ADGRC1; flamingo homolog 2 (Drosophila); adhesion G protein-coupled receptor C1; cadheri ......
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CELSR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCELSR1
Namecadherin, EGF LAG seven-pass G-type receptor 1
Aliases HFMI2; FMI2; CDHF9; ADGRC1; flamingo homolog 2 (Drosophila); adhesion G protein-coupled receptor C1; cadheri ......
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CELSR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3240.592
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.0980.389
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2470.821
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2890.471
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.440.864
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1010.976
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3170.549
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7110.619
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1570.923
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.50.725
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9760.625
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7920.000163
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CELSR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.84.110.70.0828
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.85.19.70.199
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.517.6-8.10.64
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.727.3-19.60.3
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.218.83.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 475014.335.70.491
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.23.79.50.388
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.27.710.50.63
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCELSR1
Namecadherin, EGF LAG seven-pass G-type receptor 1
Aliases HFMI2; FMI2; CDHF9; ADGRC1; flamingo homolog 2 (Drosophila); adhesion G protein-coupled receptor C1; cadheri ......
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CELSR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCELSR1
Namecadherin, EGF LAG seven-pass G-type receptor 1
Aliases HFMI2; FMI2; CDHF9; ADGRC1; flamingo homolog 2 (Drosophila); adhesion G protein-coupled receptor C1; cadheri ......
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CELSR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CELSR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCELSR1
Namecadherin, EGF LAG seven-pass G-type receptor 1
Aliases HFMI2; FMI2; CDHF9; ADGRC1; flamingo homolog 2 (Drosophila); adhesion G protein-coupled receptor C1; cadheri ......
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CELSR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCELSR1
Namecadherin, EGF LAG seven-pass G-type receptor 1
Aliases HFMI2; FMI2; CDHF9; ADGRC1; flamingo homolog 2 (Drosophila); adhesion G protein-coupled receptor C1; cadheri ......
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CELSR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCELSR1
Namecadherin, EGF LAG seven-pass G-type receptor 1
Aliases HFMI2; FMI2; CDHF9; ADGRC1; flamingo homolog 2 (Drosophila); adhesion G protein-coupled receptor C1; cadheri ......
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CELSR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCELSR1
Namecadherin, EGF LAG seven-pass G-type receptor 1
Aliases HFMI2; FMI2; CDHF9; ADGRC1; flamingo homolog 2 (Drosophila); adhesion G protein-coupled receptor C1; cadheri ......
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CELSR1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.